The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.

As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), has selected 15 additional drugs for pr

Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country healthier and stronger."

Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team, has died at 65. | Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team,

A new Health and Human Services report is calling for greater transparency in long-term care ownership, calling out private equity investors.

The Biden Administration announced the next batch of 15 prescription drugs that will be included in price negotiations with companies — with the aim of lowering costs for people covered by Medicare.

The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, cancers, and various other conditions were among the 15 drugs the Biden administration selected for the next round of Medicare price negotiation.